Akeso says Phase III HARMONi-GI1 overall survival data for ivonescimab in first-line biliary tract cancer wins ESMO late-breaking slot

By Public Technologies
  • Akeso flagged positive overall survival results from a Phase III study of ivonescimab in first-line advanced biliary tract cancer.
  • The data have not been presented yet; they are scheduled as a late-breaking oral at ESMO 2026 in Madrid on Oct. 25, 2026.
  • The trial compared ivonescimab with chemotherapy against durvalumab with chemotherapy, positioning ivonescimab for competitive first-line use.
  • Akeso also outlined broader ESMO 2026 exposure for ivonescimab and cadonilimab, supporting its bispecific antibody portfolio strategy.


Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Akeso Inc. published the original content used to generate this news brief via PR Newswire (Ref. ID: 202609211946PR_NEWS_USPR_____CN53413) on September 21, 2026, and is solely responsible for the information contained therein.

Capital.com is an execution-only brokerage platform and the content provided on the Capital.com website is intended for informational purposes only and should not be regarded as an offer to sell or a solicitation of an offer to buy the products or securities to which it applies. No representation or warranty is given as to the accuracy or completeness of the information provided.

The information provided does not constitute investment advice nor take into account the individual financial circumstances or objectives of any investor. Any information that may be provided relating to past performance is not a reliable indicator of future results or performance.

To the extent permitted by law, in no event shall Capital.com (or any affiliate or employee) have any liability for any loss arising from the use of the information provided. Any person acting on the information does so entirely at their own risk.

Any information which could be construed as “investment research” has not been prepared in accordance with legal requirements designed to promote the independence of investment research and as such is considered to be a marketing communication.